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Abstract 
Background: The emergence and spread of Plasmodium falciparum resistance to artemisinin‑based combination 
therapy in Southeast Asia prompted the need to develop new endoperoxide‑type drugs.
Methods: A chemically diverse library of endoperoxides was designed and synthesized. The compounds were 
screened for in vitro and in vivo anti‑malarial activity using, respectively, the SYBR Green I assay and a mouse model. 
Ring survival and mature stage survival assays were performed against artemisinin‑resistant and artemisinin‑sensitive 
P. falciparum strains. Cytotoxicity was evaluated against mammalian cell lines V79 and HepG2, using the MTT assay.
Results: The synthesis and anti‑malarial activity of 21 new endoperoxide‑derived compounds is reported, where 
the peroxide pharmacophore is part of a trioxolane (ozonide) or a tetraoxane moiety, flanked by adamantane and a 
substituted cyclohexyl ring. Eight compounds exhibited sub‑micromolar anti‑malarial activity  (IC50 0.3–71.1 nM), no 
cross‑resistance with artemisinin or quinolone derivatives and negligible cytotoxicity towards mammalian cells. From 
these, six produced ring stage survival < 1% against the resistant strain IPC5202 and three of them totally suppressed 
Plasmodium berghei parasitaemia in mice after oral administration.
Conclusion: The investigated, trioxolane–tetrazole conjugates LC131 and LC136 emerged as potential anti‑malarial 
candidates; they show negligible toxicity towards mammalian cells, ability to kill intra‑erythrocytic asexual stages of 
artemisinin‑resistant P. falciparum and capacity to totally suppress P. berghei parasitaemia in mice.
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Background
Between 2000 and 2015, malaria incidence rates fell by 
37% and malaria mortality by 60%. These achievements 
can be largely attributed to the implementation of the 
artemisinin (ART)-based combination therapy (ACT) as 
first-line treatment of Plasmodium falciparum malaria in 
endemic countries [1]. Artemisinin and its semisynthetic 
derivatives (ARTs), e.g. artesunate (ATN) and dihydroar-
temisinin (DHA), display a much better pharmacologic 
profile than other anti-malarials in use and nowadays 
world-wide P. falciparum malaria treatment relies on 
ACT, although resistance to ARTs is now evident in sev-
eral Southeast Asian countries [2–5]. Currently, reports 
of clinical failure of ARTs in areas coincident with partner 
drug resistance are increasing [6, 7]. Resistance to ARTs 
has been associated with mutations in the Kelch protein, 
K13 (PF3D7_1343700) and manifested as delayed para-
site clearance [8].
Another relevant issue related to the widespread appli-
cation of artemisinins (ARTs) is the difficulty in main-
taining the drug supply; artemisinin is extracted from 
Artemisia annua in low yield and ART-derivatives are 
obtained by a long and expensive semi-synthesis pro-
cess [9]. These circumstances pushed efforts towards the 
development of a next generation of potent anti-malarial 
endoperoxides, equally effective against ART-susceptible 
and -resistant strains of P. falciparum, as well as safer 
and cheaper than ARTs. Synthetic trioxolanes [10] and 
tetraoxanes [11] are particularly promising in this con-
text, exhibiting anti-malarial activity similar to ARTs. 
Amenable synthetic routes have been developed to both 
compound classes, enabling the preparation of chemi-
cally diverse libraries of analogues for further struc-
ture–activity relationship analysis, selection of leads, 
optimization and development into anti-malarial drugs 
or drug-candidates. This approach has yielded ozonides 
OZ277 (arterolane) [12] and OZ439 (artefenomel) [13], 
but recent studies reported that OZ277 and OZ439 are 
compromised by the presence of K13 mutations due to 
potential cross-resistance with DHA [13–15].
In a recent study, three synthetic trioxolanes were 
tested in vivo against a mouse model infected with arte-
misinin resistant parasites and the compounds showed 
high efficacy in clearing the infection [16]. These results 
inspired the expansion of the library of compounds and 
further investigation of their efficacy against artemisinin-
resistant (ART-R) P. falciparum strains.
The synthesis and anti-malarial activity of an endop-
eroxide-type library of compounds (trioxolanes and 
tetraoxanes) is reported. These can be easily synthesized 
from relatively cheap starting materials (preparation of 
the 21 compounds requires from 3 to 6 synthetic steps, 
depending on the cyclohexyl substitution).
Methods
Synthesis
The procedures for the preparation of the trioxolane- and 
tetraoxane-derived compounds were developed by us or 
adapted from the literature [17]. Details for the synthe-
sis and chemical characterization of the 21 peroxide-type 
compounds and their precursors are included as Addi-
tional file 1.
Evaluation of the cytotoxicity against mammalian cells
Cytotoxicity was assessed on the mammalian cell lines 
HepG2-A16 (human hepatoma) and V79 (Chinese 
hamster lung), using a MTT based assay, as previously 
described [18]. Tests were conducted in triplicate for each 
compound, at a range of concentrations (1  mM–1.372 
μM), and with culture media containing 0.5% DMSO (no 
drug). V79 and HepG2 cell lines were incubated for 24 
and 48 h, respectively (media changed at 24 h intervals). 
Absorbance was read at 570 nm on a multi-mode micro-
plate reader (Triad, Dynex Technologies), to produce 
a log dose-dependence curve. The  LD50 value for each 
compound was estimated by non-linear interpolation of 
the dose-dependence curve (GraphPad Software).
Parasite cultivation
Laboratory-adapted P. falciparum 3D7 (chloroquine and 
mefloquine sensitive), Dd2 (chloroquine-resistant, meflo-
quine-resistant), IPC5202 (MRA-1240, MR4, ATCC 
® Manassas Virginia) and IPC4912 (MRA-1241, MR4, 
ATCC ® Manassas Virginia) (artemisinin-resistant P. falci-
parum) were continuously cultured and sorbitol synchro-
nized, as previously described [19].
IC50 determination
Staging and parasitaemia were determined by light 
microscopy of Giemsa-stained thin blood smears. Anti-
malarial activity was determined using the SYBR Green 
I assay, as previously described [20]. Briefly, early ring 
stage parasites (> 80% of rings) were challenged with a 1:3 
serial dilution of each compound, in concentrations rang-
ing from 10,000–0.169  nM. Fluorescence intensity was 
measured with a multi-mode microplate reader (Triad, 
Dynex Technologies), with excitation and emission wave-
lengths of 485 and 535 nm, respectively, and analysed by 
nonlinear regression using GraphPad Prism to determine 
 IC50 values.
Ring (RSA) and mature‑stage (MSA) survival assay
Ring-stage survival assays (RSA) were carried out as 
described in [21], with modifications. Parasite cultures 
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were synchronized once, with 5% sorbitol, and in the next 
reinvasion cycle, twice, with a 6  h interval. Parasites at 
the ring-stage (< 10 h) or mature-stage (> 36 h) post-inva-
sion (1% parasitaemia and 2% haematocrit) were exposed 
during 6  h to 700  nM dihydroartemisinin (DHA) or to 
≅ 10 × IC50 of each of the tested compounds. Then, plates 
were centrifuged and supernatant replaced by drug-free 
culture media. After additional incubation during 66  h 
for ring-stage, and 42  h for mature-stage, susceptibil-
ity was assessed microscopically on Giemsa-stained thin 
blood smears by estimating the percentage of viable para-
sites that developed into a second generation of rings or 
trophozoites.
In vivo anti‑malarial assays
In vivo tests were performed following the Guidelines 
for Ethical Conduct in The Care and Use of Animals of 
the Federal University of Rio Grande do Norte—Bra-
zil (CEUA/UFRN/46/2013). Evaluation of anti-malarial 
activity in  vivo was carried out using the Peters’ 4-day 
suppressive test [22], with modifications, as previously 
described [23–25]. Swiss albino mice were infected with 
Plasmodium berghei NK65 and randomly allocated to 
groups of five animals. Animals were treated with 50 mg/
kg/day of each of the tested compounds (dissolved in 
PBS containing 1% DMSO), administrated orally, for four 
consecutive days. The control group was treated with a 
solution of PBS/1% DMSO. On days 5 (D5), 7 (D7) and 
10 (D10) after parasite inoculation, tail blood smears 
were Giemsa-stained and examined microscopically to 
estimate parasitaemia. Acute toxicity testing was car-
ried out to determine adverse effects due to compounds 
(including weight loss, hair appearance, skin wounds and 
behavioural changes), and recorded daily [26].
Results
Synthesis
A representative library of 21 compounds with potential 
antiplasmodial activity was designed and synthesized. 
All compounds proposed include a peroxide-type phar-
macophore (trioxolane- or tetraoxane-based) flanked 
by adamantane and a suitably functionalized cyclohexyl 
ring. The endoperoxides LC50, LC67 and LC140 were 
used as intermediates for the preparation of other com-
pounds, altering the cyclohexyl substitution. The syn-
thesis of the trioxolane–tetrazole, tetraoxane-tetrazole 
and trioxolane–saccharyl conjugates was achieved using 
a convergent approach whereby the endoperoxide and 
tetrazole or saccharyl building blocks were separately 
prepared and then linked to form the desired endoper-
oxide-based targets. In our library, the chemical diversity 
is introduced in the cyclohexyl moiety (Fig. 1). Synthetic 
trioxolanes (compounds LC28, LC50, LC67, LC68, LC92, 
LC93, LC94, LC95, LC129, LC130, LC131, LC132, LC136, 
LC142, MIS13, MIS14, MIS15, MIS16; Fig. 1: Scheme 1) 
and tetraoxanes (compounds LC140, LC163; Fig.  1: 
Scheme 2) were prepared using the synthetic approaches 
depicted in Schemes 1 and 2.
Cytotoxicity against mammalian cells
In order to evaluate the selectivity of compounds for 
parasite over mammalian cells, their cytotoxicity was 
assessed in human hepatocellular carcinoma (HepG2) 
and hamster lung (V79) cells. All tested compounds 
presented low or undetectable cytotoxicity in both cell 
lines. The selectivity index (SI) for each compound is 
expressed by the ratio between its cytotoxicity and anti-
plasmodial activity (SI = LD50 in mammalian cells/IC50 P. 
falciparum). At a maximum dose of 1 mM, only MIS13 
and MIS14 revealed some in vitro cytotoxicity, inducing 
a decrease in HepG2 survival of ≅ 30%. The remaining 
compounds displayed high selectivity indexes (SI > 273) 
(Additional file 1).
In vitro activity of new endoperoxides
Initially, all 21 synthesized endoperoxides were screened 
for their in  vitro anti-malarial activity against chloro-
quine-susceptible (3D7) and multidrug-resistant (Dd2) 
P. falciparum strains (Table  1; Additional file  1), using 
a whole-cell SYBR Green I based assay. The  IC50 val-
ues were calculated from at least 3 experiments, car-
ried out in triplicates. The obtained  IC50 for the control 
drug CQ against 3D7 and Dd2, fell within the expected 
range (Table  1). Among the 21 compounds, 12 showed 
sub-micromolar activity  (IC50 < 1  μM) against both 3D7 
and Dd2 strains, with 9 exhibiting  IC50 values < 100 nM 
(LC92, LC129, LC130, LC131, LC132, LC136, LC163, 
MIS13 and MIS14) (Additional file  1). These 9 com-
pounds were further tested against two ART-R strains 
(IPC5202 and IPC4912) and, except for MIS14, pre-
sented very promising anti-malarial activity, with  IC50 
values ranging from 0.3 to 71.1 nM (Table 1). In addition 
to sub-micromolar activity, these eight compounds also 
demonstrated high selectivity towards the parasite (Addi-
tional file 1) and a low resistance index (RI; ranging from 
0.10 to 2.43), indicating absence of cross resistance with 
ARTs (Table 1). Thus, compounds LC92, LC129, LC130, 
LC131, LC132, LC136, LC163 and MIS13 were selected 
for further studies.
Ring and mature‑stage survival rate
Resistance to ARTs in vivo is characterized by a delayed 
parasite-clearance time. Up to now this phenotype 
could not be evidenced using the standard in  vitro 
48–72 h inhibitory assay, expressed as  IC50 [13, 21, 
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27–31], probably due to the elevated resistance of the 
very young-ring stages of the parasites. Hence, the phe-
notypic assay, ring-stage survival assay (RSA), was 
used to assess the activity of the 8 compounds selected 
(LC92, LC129, LC130, LC131, LC132, LC136, LC163 
and MIS13). Young ring-stage survival of P. falcipa-
rum parasites carrying the K13 R539T polymorphism 
(IPC5202) associated with high RSA and 3D7 were chal-
lenged during 6 h with 700 nM DHA or a concentration 
of 10xIC50 of each of the tested compounds. Generally, 
the 8 endoperoxides demonstrated higher activity than 
DHA against the resistant strain (Fig.  2a). It is gener-
ally accepted that a survival rate RSA < 1% corresponds 
to a susceptible behaviour. The 8 endoperoxides were 
able to reduced RSA < 1% (Fig.  2a) in both ART-R and 
ART-S strains (IPC5202 and 3D7). On the other hand, 
DHA exposure resulted in a higher survival rate of the 
ART-R (up to 25%) than the susceptible 3D7. Concerning 
the new trioxolanes, no cross-resistance with DHA was 
apparent for parasites carrying the K13 R539T mutation 
Scheme 1
Scheme 2
Fig. 1 Structural representations of the trioxolanes, tetraoxanes and derivatives of artemisinin investigated in this work. Scheme 1: Representation 
of the synthetic routes to the trioxolanes prepared; reagents and conditions: (i) Pyridine, MeONH2, MeOH, r.t; (ii) 1,4‑Cyclohexane, O3, DCM/
pentane, − 78 °C; (iii) LC133, O3, DCM/pentane, − 78 °C; (iv) Ethyl 4‑oxocyclohexanecarboxylate, O3, DCM/pentane, − 78 ºC; (v) LC64, AcOH, DCE, 
NaBH(OAc)3, r.t.; (vi) Trichloroacetic acid, DCM, H2O, r.t.; (vii) 5‑Aminotetrazole, DCE, AcOH, NaBH(OAc)3, r.t.; (viii) LiBH4, Et2O, LiBH(Et)3, r.t.; (vi) KOH 
(3M), MeOH, 60 °C; (x) Phthalimide, Ph3P, DIAD, THF, 0ºC; (xi) Hydrazine hydrate, chloroform/MeOH, 60 °C; (xii) 3‑Chloro‑1,2‑benzisothiazole‑1,1‑di
oxide, THF, 60 °C; (xiii) 3‑Chloro‑1,2‑benzisothiazole‑1,1‑dioxide, TEA, toluene, 45 °C; (xiv) 2‑Methyl‑2H‑tetrazole‑5‑amine, TEA, mesyl chloride, THF, 
60 ºC; (xv) 5‑Chloro‑1‑phenyl‑tetrazole, TEA, mesyl chloride, THF, 60 °C; (xvi) tert‑Butyl(4‑aminobutyl)carbamate, EDC, HOBt, N‑methylmorpholine, 
DCM, r.t.; (xvii) Trichloroacetic acid, DCM, H2O, r.t.; (xviii) Butylamine, EDC, HOBt, N‑Methylmorpholine, DCM, r.t.; (ix) 1‑Aminobutane, EDC, HOBt, 
N‑Methylmorpholine, DCM, r.t.; Scheme 2: Representation of the synthetic route to tetraoxanes LC140 and LC163; reagents and conditions: (i) 
HCO2H, CH3CN, H2O2 50%, 0 °C; (ii) 1,4‑Cyclohexanone, DCM, HBF4, 0 °C; (iii) 5‑Aminotetrazole, DCE, AcOH, NaBH(OAc)3, r.t.
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Table 1 Antiplasmodial activity in vitro (IC50) against resistant and sensitive P. falciparum strains
Compound P. falciparum IC 50 ± SD (nM) Resistance Index
ID Structure Dd2 3D7 IPC5202 IPC4912 RI a RI b RI c
LC92 22.6 ± 2.6 26.7 ± 2.4 37.7 ± 9.9 34.9 ± 7.9 0.85 1.41 1.31
LC129 43.2 ± 0.8 42.9 ± 3.9 36.4 ± 0.6 33,7 ± 0.4 1.01 0.85 0.79
LC130 24.8 ± 17.2 23.3 ± 15.2 8.2 ± 1.9 2.4 ± 1.6 1.06 0.35 0.10
LC132 26.6 ± 15.9 24.2 ± 12.8 25.0 ± 7.4 19.7 ± 3.4 1.10 1.03 0.81
LC131 2.1 ± 1.9 2.9 ± 2.4 3.4 ± 2.1 4.8 ± 1.2 0.72 1.17 1.66
MIS13 3.4 ± 3.0 7.4 ± 6.5 1.7 ± 1.1 0.3 ± 0.3 0.46 0.23 0.04
LC136 2.5 ± 1.3 2.8 ± 1.2 6.1 ± 1.9 6.8 ± 2.3 0.89 2.18 2.43
LC163 43.5 ± 3.0 63.0 ± 0.7 71.1 ± 1.1 18.6 ± 16.9 0.69 1.13 0.30
ART 2.5 ± 0.1 4.0 ± 0.1 33.3 ± 8.0 13.3 ± 2.2 0.62 8.32 3.32
ATN 4.6 ± 1.4 5.1 ± 0.1 3.4 ± 0.1 3.9 ± 1.2 0.90 0.67 0.76
DHA 4.2 ± 0.5 4.7 ± 1.5 6.2 ± 1.6 3.7 ± 2.0 0.89 1.32 0.79
CQ 340.1 ± 20.7 15.8 ± 0.8 n.d. n.d. 21.5 n.d. n.d.
SD standard deviation, ART artemisinin, ATN artesunate, DHA dihydroartemisinin, CQ chloroquine, n.d. not determined
RIa: resistance index = IC50 (Dd2)/IC50 (3D7)
RIb: resistance index = IC50 (IPC5202)/IC50 (3D7)
RIc: resistance index = IC50 (IPC4912)/IC50 (3D7)
Page 6 of 11Lobo et al. Malar J  (2018) 17:145 
(Table 1). However, for the tetraoxane LC163 both ART-S 
and ART-R strains exhibited ring-stage survival above 1% 
(6.9 ± 1.6 and 2.0 ± 1.9, respectively), although no cross-
resistance was observed (Table 1). Mature-stages of both 
the ART-S and ART-R parasites exhibited full susceptibil-
ity to all of the 8 selected endoperoxides, which appear to 
offer a better performance than DHA (Fig. 2b).
In vivo anti‑malarial activity
The 8 best performing compounds were adminis-
tered orally at 50  mg/kg/day and demonstrated a high 
inhibition capacity, with parasitaemia ranging from 0 
to 0.19 ± 0.12% on day 5 post-infection (Table  2). The 
efficacy difference was very significant (P < 0.0002), 
compared to the vehicle-treated mice; the control inhib-
ited parasitaemia by 1.51% ± 0.22 (Table  2). On day 10 
post-infection, mice in the control group developed 
significant parasitaemia (5.65–6.6%), whereas 5 of the 
compounds led to an appreciable reduction in parasitae-
mia (0.31 ± 0.10–1.32 ± 1.24%) and the remaining 3 com-
pounds completely suppressed parasitaemia (Table  2). 
Although at a low level, in the group treated with LC92 
Fig. 2 Ring‑stage (RSA) and mature‑stage (MSA) survival rate, expressed as the percentage of viable parasites. Rings (a) and trophozoites (b) were 
treated with a pulse of 700 nM of DHA or (10 × IC50) synthetic endoperoxides in strains 3D7 and IPC5202
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5 animals developed parasitaemia from day 5 onwards. 
In the group treated with MIS13 only 1/5 mice pre-
sented parasitaemia on day 5, and by day 10 the five mice 
were cured. Even though MIS13 was the most cytotoxic 
in vitro against HepG2 cells, from the range of 21 com-
pounds tested, no adverse effects were observed in vivo. 
During the experimental procedure, the animals were 
monitored daily and no adverse effects were observed 
for any of the tested compounds. Appreciable in  vivo 
anti-malarial activity was observed for the two sacharyl 
substituted compounds (LC129, LC130). LC129 kept 
parasitaemia at a low level, but failed to completely sup-
press it. On the other hand, LC130 was able to suppress 
parasitaemia until day 5 but recrudescence occurred 
on day 7 (2/5 mice were parasitemic) and by day 10 all 
animals presented parasitaemia (Table  2), although sig-
nificantly lower than in the control group (P = 0.017). 
In the group treated with LC132 and LC163 recrudes-
cence also occurred on day 10. However, a strong in vivo 
anti-malarial effect against P. berghei was observed with 
LC131 and LC136, with complete suppression of parasi-
taemia throughout the experiment (10 days), suggesting 
that sufficient plasma concentration was attained, hence 
indicating a promising bioavailability and pharmacoki-
netic profile.
Discussion
The new peroxide-type compounds tested have shown 
low or undetectable cytotoxicity against human hepato-
cellular carcinoma (HepG2) and hamster lung (V79) cell 
lines. It is generally accepted that, if SI > 10, the observed 
pharmacological activity is not due to cytotoxicity [32, 
33]. Since the SI values calculated for the compounds 
are considerably higher, that the activity exhibited by the 
compounds is unlikely due to general cellular toxicity, but 
rather due to specific antiplasmodial activity. The eight 
endoperoxides selected from our library that met the cri-
teria—SI > 100 and  IC50 < 100 nM [34] were evaluated for 
in vitro and in vivo efficacy, demonstrating  IC50 values in 
the range of those exhibited by ARTs and a strong cura-
tive effect in vivo, with a parasitaemia reduction on day 
10 above 76% (Tables 1, 2). These 8 compounds were par-
ticularly active against intra erythrocytic stages, across all 
four P. falciparum strains tested, with  IC50 values ranging 
from 0.3 to 71.1 nM and high selectivity for the parasite. 
Even though LC136 presented RIs > 1 (up to 2.43), the 
values fall within the range of those exhibited by ARTs 
for the same parasite strains (0.62–8.32; Table 1).
Results show that the nature of the cyclohexyl substitu-
ent affects antiplasmodial activity. For instance, LC92 
exhibited  IC50 values up to 11 times higher than the 
control drugs (ART derivatives) while its counterpart 
MIS13 was shown to be as effective as ARTs across the 
four parasite strains, with no apparent cross resistance. 
This increased activity probably arises from an improve-
ment in pharmacokinetic properties due to: (i) a more 
substituted amino functionality that increases the overall 
hydrophilicity and favours protonation in acidic environ-
ments; and (ii) to the BOC-protection of the side chain 
that facilitates the transport of MIS13 through the cell 
membrane (compared to LC92) [35]. Although MIS13 
induced a slight cytotoxicity in  vitro (30% reduction 
in survival of HepG2 cells at 1  mM), no adverse effects 
were observed in  vivo. Only 1/5 animals treated with 
MIS13 presented parasitaemia on day 5, which gradu-
ally decreased until 0% by day 10, whereas in the group 
treated with LC92 all animals presented residual parasi-
taemia during the 10 days.
Table 2 In vivo anti-malarial activity against Plasmodium berghei 
SD standard deviation
a Control: treated with PBS 1% DMSO
b Parasitaemia reduction compared to untreated control group
Compound Dose (mg/kg/day) Mean parasitaemia ± SD (% inhibition of parasite growth)b
Day 5 Day 7 Day 10
Controla 1.51 ± 0.22 3.58 ± 0.81 5.65 ± 0.43
LC92 50 0.02 ± 0.05 (98.34) 0.46 ± 0.60 (86.99) 0.77 ± 0.26 (86.27)
LC129 50 0.19 ± 0.12 (87.60) 1.76 ± 1.36 (50.69) 1.32 ± 1.24 (76.67)
LC130 50 0 (100) 1.4 ± 0.94 (60.83) 1.32 ± 0.24 (76.67)
LC131 50 0 (100) 0 (100) 0 (100)
LC132 50 0 (100) 0 (100) 0.31 ± 0.10 (94.46)
LC136 50 0 (100) 0 (100) 0 (100)
MIS13 50 0.11 ± 0.19 (92.56) 0.05 ± 0.10 (98.60) 0 (100)
LC163 50 0 (100) 0 (100) 0.2 ± 0.13 (96.46)
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Compounds LC131, LC132 and LC136, comprising a 
tetrazole moiety linked to the trioxolane pharmacophore, 
exhibited an excellent anti-malarial profile, both in vitro 
and in  vivo. Tetrazole-containing drugs and drug-can-
didates are thriving in medicinal chemistry [36, 37] and 
many are effective therapeutic agents for various patho-
genesis, showing a wide range of pharmacological activi-
ties, such as antimicrobial, antibacterial, antifungal, and 
antitubercular [38–41]. The tetrazole moiety has been 
described as metabolically stable, featuring in the struc-
ture of several drugs and drug-candidates, usually as a 
surrogate for the carboxylic acid functionality, and gen-
erally improving the pharmacokinetic profile [42, 43]. 
The higher metabolic stability conferred by the tetrazole 
[42–46] could be improving the pharmacological prop-
erties or increasing accumulation (due to the electron-
withdrawing properties). In line with this, a better in vivo 
anti-malarial profile for the tetrazole conjugates LC131, 
LC132, LC136 and LC163, was observed, particularly for 
trioxolanes LC131 and LC136, which exhibited a cura-
tive effect in mice with total suppression of parasitaemia 
from day 5 to day 10. To assess the nature of the tetra-
zole moiety contribution to the anti-malarial activity, the 
tetrazole building blocks (LC133 and LC126II; Additional 
file 1) were separately tested and revealed to be devoid of 
antiplasmodial activity. The ether-linked tetrazolyl–tri-
oxolane conjugate LC132 was up to 12 times less active 
than LC131 or LC136 and, in vivo, allowed recrudescence 
on day 10. Probably, this compound is less stable due to 
the possibility of thermally-induced 1,3-isomerization of 
the alkyl-trioxolane moiety [47], as the C(alkyl)-O bond 
is relatively weak due to the electron withdrawing effect 
of the tetrazole heterocycle. Comparatively, the amino-
linked conjugates LC131 and LC136 are chemically more 
stable. LC131 and LC136 exhibited an exceptionally good 
in  vitro anti-malarial profile against both ART-R and 
ART-S parasites, comparable to that of the control drugs 
ART, ATN and DHA. The ability of the amino group to 
protonate in the acidic environment of the food vacuole 
probably confers additional anti-malarial efficacy by facil-
itating accumulation, placing the two new compounds 
as promising drug candidates. In conjugates LC131 and 
LC136 the heteroaromatic substituent is a 2-substituted 
5-aminotetrazole (in LC136 the tetrazole ring exhibits 
tautomerism, with the 2-H tautomer being favoured in 
the gas phase) [48]. An additional interest of this substi-
tution pattern resides in the potential of 2,5-disubstituted 
tetrazoles to act as probes. It was demonstrated that, 
upon narrow-band UV-induced irradiation, 2,5-dissub-
stituted tetrazoles generate nitrile imine dipolar species 
in  situ, via extrusion of  N2, which may then react with 
an alkene dipolarophile through a 1,3-dipolar cycload-
dition reaction [49, 50]. Thus, the trioxolane–tetrazole 
conjugates LC131 and LC136 could also be developed as 
tags for mechanistic studies.
Compound LC163 is a tetraoxane–tetrazole conjugate 
structurally related to the trioxolane LC136. The results 
show that replacement of the trioxolane by a tetraoxane 
ring, as the pharmacophore, leads to a decreased anti-
malarial activity, both in vitro and in vivo. Even though 
the RIs for LC163 are low, the corresponding  IC50 val-
ues for the resistant strains IPC4912 and IPC5202 are, 
respectively, 3 and 42 times higher than those found for 
trioxolane LC136. The reason for this difference is still 
elusive [51], so detailed structural studies on both com-
pounds are planned.
The saccharyl substituent present in compounds LC129 
and LC130 is also electron withdrawing and metaboli-
cally stable. Additionally, the saccharyl system is ther-
mally and photochemically more stable than the tetrazole 
system and is generally found to improve the overall sta-
bility of the molecule [27], although it is worth noting 
that LC129 is prone to Chapman-type isomerization [27]. 
The anti-malarial profile exhibited by the trioxolane–sac-
charyl conjugates LC129 and LC130 was slightly inferior 
to that of their tetrazole analogues (Tables  1, 2). As for 
trioxolane–tetrazoles, the saccharyl building block was 
tested separately and revealed to be devoid of antiplas-
modial activity (Additional file 1). Hence, the anti-malar-
ial activity demonstrated by the trioxolane–saccharyl 
conjugates can be ascribed to the presence of the triox-
olane pharmacophore.
Structural analogies between DHA, trioxolanes and 
tetraoxanes may accommodate similar modes of action, 
hence some level of cross resistance [10, 28–31, 52]. In 
the light of this, it was investigated whether parasites 
expressing variant forms R539T (IPC502) and I543T 
(IPC4912) of K13 are cross-resistant to the newly synthe-
sized trioxolanes and tetraoxanes.
ARTs resistance cannot be evidenced by the standard 
in vitro  IC50 assay [13, 21, 27–31]. Critical for the devel-
opment of anti-malarials is the evaluation of their activ-
ity against ART-R parasites, which has been defined 
as delayed parasite clearance in patients [53]. Slow 
parasite clearance of P. falciparum malaria in patients 
results from reduced ring-stage susceptibility [53–56], 
this increasing the need for new compounds with a low 
RSA. The mutation R539T (present in IPC5202) is one 
of the k13 mutations that confer high levels of DHA 
resistance in vitro [31, 52, 57]. We explored the suscep-
tibility of the IPC5202 ring and mature-stage parasites 
(RSA and MSA) to the best performing compounds. As 
depicted in Fig.  2, the endoperoxides selected demon-
strated higher activity than DHA, both against ring and 
mature stages. As expected, DHA exposure resulted in 
a higher survival rate of IPC5202 (up to 25%) than for 
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3D7 [58, 59], though lower than in other reports [60]. 
A survival rate RSA < 1% is generally considered as sus-
ceptible behaviour. The tested trioxolanes were able to 
reduce ring survival to less than 1% in both resistant and 
susceptible strains (IPC5202 and 3D7), hence no cross-
resistance with DHA is apparent, even in parasites car-
rying the K13 mutation R539T. This notable observation 
indicates that our compounds have an improved range of 
activity, compared to other trioxolanes in use, namely the 
registered drug OZ277, which is compromised by K13 
mutations [31]. Regarding the tetraoxane LC163, both 
the K13 wild type (3D7) and mutant (IPC5202) parasites 
presented RSA > 1% (though not significantly different). 
These observations are in agreement with data recently 
published showing that a tetraoxane also allowed growth 
above 1% in RSA assay in a strain carrying K13 R538T 
mutation [61]. The results indicate therefore that the 
anti-malarial activity of the newly synthesized endoper-
oxides is not compromised by the K13 mutation R539T, 
a mutation that confers high levels of in vitro resistance 
and has been associated with delayed parasite clearance 
in patients [8, 62–65]. The mature-stage assay (MSA) 
evidenced nearly full susceptibility of the two strains to 
all of the eight compounds (Fig. 2). Thus, all compounds 
performed better than DHA. Typically, DHA allows a 
≅ 1% of viable mature-stage [13, 21]. ARTs resistance 
phenotypes are associated with a decreased susceptibility 
of the ring stage to enter dormancy, a decreased sensitiv-
ity of mature-stage parasites and a faster recovery from 
dormancy [66, 67]. Currently these parameters are being 
addressed in order to gather more information regarding 
the mode of action of the more promising compounds.
As expected, no cross-resistance of the proposed com-
pounds with quinolone-type anti-malarials is foreseeable, 
as the calculated RIs for Dd2 and 3D7 were ≅1 (Table 1), 
which is considerably lower than the RI determined for 
CQ (21.5) [20, 68].
Conclusion
The compounds LC131, LC136 and MIS13 demonstrated 
to be the most promising; they showed nanomolar activ-
ity against ART-resistant P. falciparum parasites, negligi-
ble toxicity towards mammalian cells, totally suppressed 
P. berghei parasitaemia in mice and showed no cross 
resistance with CQ and ARTs.
These compounds can be easily prepared from rela-
tively cheap starting materials. For instance, LC136 
requires only 3 synthetic steps. On the other hand, ART-
derivatives are obtained from the expensive natural prod-
uct artemisinin through semi-synthesis. Thus, besides the 
excellent pharmacologic properties, an anti-malarial per-
oxide-type formulation based on trioxolane LC136 could 
be cheaper than those based on current ART-derivatives, 
while offering a comparable, or even better, anti-malarial 
profile.
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